INmune BioINMB +1.54%53 EBIT per Share is $-1.05 as of Mar. 2026. GuruFocus rates INMB with a GF Score™ of 53/100 and a GF Value™ of $1.83 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 1,181 Biotechnology companies, INmune Bio ranks worse than 64.44% on this metric.
INmune Bio's EBIT per Share for the
three
months ended in Mar. 2026 was $-0.22.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.05.
During the past 3 years, the average EBIT per Share Growth Rate was 4.90% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -4.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for INmune Bio's EBIT per Share or its related term are showing as below:
INMB'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -256.3 Med: -17.5 Max: 4.9
Current: 4.9
During the past 10 years, the highest 3-Year average EBIT per Share Growth Rate of INmune Bio was 4.90% per year. The lowest was -256.30% per year. And the median was -17.50% per year.
INMB's 3-Year EBIT Growth Rate is ranked worse than 64.44% of 1181
companies
in the Biotechnology industry
Industry Median: 15.5
vs INMB: 4.90
INmune Bio's EBIT for the
three
months ended in Mar. 2026 was $-5.81 Mil.
INmune Bio (NAS:INMB) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
INmune Bio EBIT per Share Related Terms
INmune Bio EBIT per Share Historical Data
* Premium members only.
The historical data trend for INmune Bio's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.05
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INmune Bio (INMB) has a EBIT per Share of $-1.05 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on INmune Bio and its competitors. According to the industry distribution chart, INmune Bio ranks #761 out of 1181 companies in the Biotechnology industry, placing it in the top 64.4%.
Is INmune Bio's EBIT per Share too high?
INmune Bio's current EBIT per Share is $-1.05. Based on the distribution chart, INmune Bio ranks #761 out of 1181 companies in the Biotechnology industry, which is below the industry midpoint. Overall, INmune Bio has a GF Score™ of 53/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does INmune Bio's EBIT per Share compare to GRCE and NTRB?
According to the Biotechnology industry distribution chart, INmune Bio ranks #761 out of 1181 companies for EBIT per Share. This places INmune Bio in the lower half of its industry. The industry median EBIT per Share is 15.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.50, based on 1,181 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on INmune Bio and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. INmune Bio's current EBIT per Share is $-1.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is INmune Bio stock overvalued right now?
Based on GuruFocus' analysis, INmune Bio (INMB) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.83, compared to a current price of $1.65 — trading 10.1% below its estimated fair value. The current EBIT per Share is $-1.05. INmune Bio's overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For INmune Bio (INMB), the current EBIT per Share is $-1.05 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is INmune Bio (INMB) Overvalued in 2026?
Based on GuruFocus' analysis, INmune Bio stock appears to be undervalued.
The current stock price of $1.65 is trading 10.1% below its estimated GF Value™ of $1.83.
GuruFocus considers INmune Bio to be Modestly Undervalued.
Key valuation signals for INMB:
EBIT per Share: $-1.05
GF Value™: $1.83 vs. price of $1.65 (10.1% below fair value)
No single metric tells the full story. See the INMB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
53GF Score
Get the complete analysis for INMB
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INMB has been successfully added to your 
